Research Insight
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced final results from a retrospective study
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA(R) (exenatide) injection was not increased compared to initiators...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read